CELLULAR BIOMEDICINE GROUP, INC. (NASDAQ:CBMG) Files An 8-K Regulation FD DisclosureItem 7.01 Regulation FD Disclosure.
CELLULAR BIOMEDICINE GROUP, INC. (NASDAQ:CBMG) Files An 8-K Regulation FD Disclosure
On January 9, 2017, Cellular Biomedicine Group, Inc. (the “Company”) issued a press release announcing the commencement of patient enrollment in China for its CALL-1 (“CAR-T against Acute Lymphoblastic Leukemia”) Phase I clinical trial utilizing its optimized proprietary C-CAR011 construct of CD19 chimeric antigen receptor T-cell (“CAR-T”) therapy for the treatment of patients with relapsed or refractory (r/r) CD19+ B-cell Acute Lymphoblastic Leukemia. A copy of the press release is attached hereto as Exhibit 99.1.
Attached as Exhibit 99.2 to this Current Report is the form of presentation that the Company will be using in connection with its presentation to certain potential investors at the 9th Annual Biotech Showcase conference on January 10, 2017 in San Francisco, California.
Item 9.01. Financial Statements and Exhibits.
(d)Exhibits
99.1 Press Release, dated January 9, 2017
99.2 Presentation
About CELLULAR BIOMEDICINE GROUP, INC. (NASDAQ:CBMG)
Cellular Biomedicine Group, Inc. (CBMG) is a biomedicine company. The Company is engaged in the development of treatments for cancerous and degenerative diseases utilizing cell-based technologies. The Company operates in Biomedicine Cell Therapy segment. The Company’s technology includes platforms, such as Immune Cell therapy for treatment of broad range of cancers using Vaccine, T Cells Receptor (TCR) clonality analysis technology and T Central Memory Cell (Tcm) preparation methodologies, Chimeric Antigen Receptor T cell (CAR-T), and human adipose-derived mesenchymal progenitor cells (haMPC) for treatment of joint and autoimmune diseases, with primary research and manufacturing facilities in China. It is focused on developing and marketing cell-based therapies based on its cellular platforms, to treat serious chronic and degenerative diseases, such as cancer, orthopedic diseases, including osteoarthritis and tissue damage, various inflammatory diseases and metabolic diseases. CELLULAR BIOMEDICINE GROUP, INC. (NASDAQ:CBMG) Recent Trading Information
CELLULAR BIOMEDICINE GROUP, INC. (NASDAQ:CBMG) closed its last trading session up +0.05 at 13.10 with 3,563 shares trading hands.
Cellular Biomedicine Group, Inc. (CBMG) is a biomedicine company. The Company is engaged in the development of treatments for cancerous and degenerative diseases utilizing cell-based technologies. The Company operates in Biomedicine Cell Therapy segment. The Company’s technology includes platforms, such as Immune Cell therapy for treatment of broad range of cancers using Vaccine, T Cells Receptor (TCR) clonality analysis technology and T Central Memory Cell (Tcm) preparation methodologies, Chimeric Antigen Receptor T cell (CAR-T), and human adipose-derived mesenchymal progenitor cells (haMPC) for treatment of joint and autoimmune diseases, with primary research and manufacturing facilities in China. It is focused on developing and marketing cell-based therapies based on its cellular platforms, to treat serious chronic and degenerative diseases, such as cancer, orthopedic diseases, including osteoarthritis and tissue damage, various inflammatory diseases and metabolic diseases. CELLULAR BIOMEDICINE GROUP, INC. (NASDAQ:CBMG) Recent Trading Information
CELLULAR BIOMEDICINE GROUP, INC. (NASDAQ:CBMG) closed its last trading session up +0.05 at 13.10 with 3,563 shares trading hands.